MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$1,509K
Free Cash flow
-$9,979K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities and sal...
Stock-based compensation expense
Accrued expenses
Others
Negative Cash Flow Breakdown
Purchase of marketable securitie...
Payments on royalty sale liabili...
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-19,501
-13,091
-11,938
-18,700
Stock-based compensation expense
3,683
3,748
3,810
4,034
Depreciation and amortization expense
1,185
1,209
1,230
1,284
Non-cash interest associated with the sale of future royalties
814
233
696
-630
Non-cash royalty revenue
-1,523
-773
1,879
-1,737
Premium paid on marketable securities
203
281
756
0
Amortization of premiums on marketable securities
-8
-302
-20
958
Loss on disposal of property and equipment
0
0
0
0
Change in fair value of series 1 nonconvertible preferred stock
-
-
-
39
Accounts receivable
-1,275
-684
1,611
-1,451
Prepaid expenses and other current assets
769
2,468
-4,248
-1,650
Income tax receivable
-19
19
0
-24
Operating lease, right-of-use assets
-584
-567
-546
-701
Other long-term assets
-34
51
1
-2
Accounts payable
-1,076
2,478
-63
-723
Accrued expenses
3,324
-716
-5,176
2,418
Operating lease liabilities
-880
-533
-834
-147
Other long-term liabilities
8
9
9
8
Net cash used in operating activities
-9,972
-7,156
-11,699
-6,489
Purchase of marketable securities
25,510
41,950
148,624
68,621
Proceeds from maturities and sale of marketable securities
39,522
53,907
101,469
72,375
Purchase of property and equipment
7
15
143
1,458
Net cash (used in) provided by investing activities
14,005
11,942
-47,298
2,296
Proceeds from the sale of future royalties
-
-
-
0
Proceeds from october 2025 public offering, net of issuance costs of 4,802
0
0
69,948
-
Payments for debt issuance costs
-
-
-
0
Payments on royalty sale liability, net of imputed interest
6,034
7,039
5,856
8,362
Payments for settlement of share-based awards
0
305
97
10
Proceeds from the exercise of stock options
492
49
141
51
Net cash provided by (used in) financing activities
-5,542
-7,295
64,136
-8,321
Net increase in cash, cash equivalents and restricted cash
-1,509
-2,509
5,139
-12,514
Cash, cash equivalents and restricted cash at beginning of period
40,797
40,797
35,658
41,201
Cash, cash equivalents and restricted cash at end of period
36,779
38,288
40,797
35,658
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
and sale of...
$39,522K
(-79.25%↓ Y/Y)
Net cash (used in)
provided by investing...
$14,005K
(-63.19%↓ Y/Y)
Canceled cashflow
$25,517K
Net increase in
cash, cash...
-$1,509K
(-121.65%↓ Y/Y)
Canceled cashflow
$14,005K
Stock-based compensation
expense
$3,683K
(-74.65%↓ Y/Y)
Accrued expenses
$3,324K
(240.85%↑ Y/Y)
Non-cash royalty revenue
-$1,523K
(-175.40%↓ Y/Y)
Accounts receivable
-$1,275K
(-175.58%↓ Y/Y)
Depreciation and
amortization expense
$1,185K
(-64.11%↓ Y/Y)
Non-cash interest
associated with the sale of...
$814K
(158.18%↑ Y/Y)
Operating lease,
right-of-use assets
-$584K
(83.81%↑ Y/Y)
Other long-term
assets
-$34K
Income tax receivable
-$19K
(99.94%↑ Y/Y)
Other long-term
liabilities
$8K
(-61.90%↓ Y/Y)
Amortization of premiums on
marketable securities
-$8K
(99.45%↑ Y/Y)
Proceeds from the
exercise of stock options
$492K
(423.40%↑ Y/Y)
Purchase of marketable
securities
$25,510K
(-81.91%↓ Y/Y)
Purchase of property and
equipment
$7K
(-99.94%↓ Y/Y)
Net cash used in
operating activities
-$9,972K
(21.99%↑ Y/Y)
Canceled cashflow
$12,457K
Net cash provided by
(used in) financing...
-$5,542K
(69.71%↑ Y/Y)
Canceled cashflow
$492K
Net loss
-$19,501K
(69.14%↑ Y/Y)
Accounts payable
-$1,076K
(-82.99%↓ Y/Y)
Operating lease
liabilities
-$880K
(-163.58%↓ Y/Y)
Prepaid expenses and
other current assets
$769K
(135.39%↑ Y/Y)
Premium paid on
marketable securities
$203K
Payments on royalty sale
liability, net of imputed...
$6,034K
(-66.71%↓ Y/Y)
Buy us a coffee
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)